General Information of Drug (ID: DMMKFUP)

Drug Name
Adatanserin Drug Info
Synonyms Adatanserin [INN]; WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
Indication
Disease Entry ICD 11 Status REF
Mood disorder 6A60-6E23 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
130918
CAS Number
CAS 127266-56-2
TTD Drug ID
DMMKFUP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [3]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [4]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [5]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [6]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [7]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [8]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [9]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [10]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [12]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [13]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [14]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [15]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [5]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [1]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [16]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [17]
Treximet DMU54QB Migraine 8A80 Approved [18]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [1]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Antagonist [1]

References

1 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
2 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
10 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
11 Clinical pipeline report, company report or official report of Lundbeck.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
14 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
15 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
16 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
17 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
18 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)